https://www.selleckchem.com/pr....oducts/bobcat339.htm
74 A/blk, p0.001) than in 2003-PIIIb. However, the addition of single doses of vincristine and asparaginase in 2010-PIIIa, even with a mandatory seven-day rest, led to more hospitalisations (0.45 A/blk, p0.001), increased risk of bacteraemia (relative-risk (RR)=7.66, p=0.005) and critical-care admissions (RR=4.31, p=0.13). Despite this, overall treatment-related mortality decreased from 2.7% to 0.8%. Taken together, the reduced phase delays allowed earlier completion of the intensive phase of treatment (standard risk 38.1 vers
Curtir
Comentario
Compartilhar
